Welcome to our dedicated page for Biomerica SEC filings (Ticker: BMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Biomerica鈥檚 journey from innovative inFoods庐 IBS diagnostics to full commercial rollout means following every SEC disclosure鈥攏ot just skimming headlines. Investors often search for R&D spending, FDA correspondence and patent updates buried deep inside the Biomerica annual report 10-K simplified or the Biomerica quarterly earnings report 10-Q filing. This page brings those details forward.
Stock Titan鈥檚 platform collects every form鈥�10-K, 10-Q, 8-K, DEF 14A, S-1鈥攁nd adds AI-powered summaries so understanding Biomerica SEC documents with AI feels intuitive. Need Biomerica insider trading Form 4 transactions before a material trial announcement? Our real-time feed flags each Biomerica Form 4 insider transactions real-time and breaks down who bought, who sold, and at what price. Curious how the board rewards leadership? The Biomerica proxy statement executive compensation section is annotated for quick ratio analysis.
Whether you鈥檙e comparing segment revenue from gastrointestinal tests quarter-over-quarter or scanning an Biomerica 8-K material events explained alert on new clinical data, the interface keeps research efficient. Practical use cases include:
- Monitoring Biomerica earnings report filing analysis to model cash runway
- Cross-checking patent disclosures against competitive pipelines
- Setting alerts for Biomerica executive stock transactions Form 4 to gauge management sentiment
Biomerica, Inc. (BMRA) reported a net loss of $4,973,000 for fiscal 2025 compared with a $5,978,000 loss in fiscal 2024, showing an improvement in operating results. The company had cash and cash equivalents of approximately $2,399,000 and working capital of about $3,135,000 at May 31, 2025, versus $4,170,000 cash and $5,527,000 working capital a year earlier, indicating reduced liquidity. During the year the company completed ATM sales of 440,687 shares for gross proceeds of ~$2,143,000 and net proceeds of ~$2,015,000. Revenue mix included over-the-counter sales of $1,049,000 and contract manufacturing of $1,070,000, with two distributors accounting for 41% of net sales in 2025. The company鈥檚 common stock trades on the Nasdaq Capital Market under the symbol BMRA and a 1-for-8 reverse split became effective April 21, 2025.
FAQ
What is the current stock price of Biomerica (BMRA)?
What is the market cap of Biomerica (BMRA)?
